- contra-indication to nasafytol® or constituents (incl. vit d): hypersensitivity or allergy to product components; - swallowing disorder or inability to take oral caps; - presence of comorbidities that imply a poor prognosis (according to clinical judgment); - pregnancy or breastfeeding women; if patient is a female of childbearing potential, patient must use an effective means of birth control (oral, intravaginal or transdermal oestrogen-progestogen combined hormonal contraceptives or intrauterine devices or sexual abstinence); - serious or active bacterial infections or documented sepsis by pathogens other than sars-cov-2; - patients participating in clinical trials of other products; patients presenting acute impairment of renal function or nephrolithiasis; alt/ast> 5 times the normal limit, or neutropenia (absolute neutrophil count < 500/ul), or thrombocytopenia (platelets < 50,000/ul).

- contra-indication to nasafytol® or constituents (incl. vit d): hypersensitivity or allergy to product components; - swallowing disorder or inability to take oral caps; - presence of comorbidities that imply a poor prognosis (according to clinical judgment); - pregnancy or breastfeeding women; if patient is a female of childbearing potential, patient must use an effective means of birth control (oral, intravaginal or transdermal oestrogen-progestogen combined hormonal contraceptives or intrauterine devices or sexual abstinence); - serious or active bacterial infections or documented sepsis by pathogens other than sars-cov-2; - patients participating in clinical trials of other products; patients presenting acute impairment of renal function or nephrolithiasis; alt/ast> 5 times the normal limit, or neutropenia (absolute neutrophil count < 500/ul), or thrombocytopenia (platelets < 50,000/ul).